ReviewJournal of Parkinson's disease2022
Parkinsonism-Hyperpyrexia Syndrome and Dyskinesia-Hyperpyrexia Syndrome in Parkinson's Disease: Two Cases and Literature Review.
Review in Journal of Parkinson's disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Acute Febrile Encephalopathy with Rigidity.Journal of intensive care medicine · 2026Review
- Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Rotigotine and parkinsonism-hyperpyrexia syndrome.Clinical parkinsonism & related disorders · 2026Article
- Dyskinesia-Hyperpyrexia Syndrome in Parkinson's Disease May Benefit from GPi Deep Brain Stimulation: A Case Report.Tremor and other hyperkinetic movements (New York, N.Y.) · 2025Article
- When Parkinson's disease encounters high fever: two case reports and literature review.American journal of translational research · 2025Article
- Akinetic crisis and withdrawal syndromes: guideline "Parkinson's disease" of the German Society of Neurology.Journal of neurology · 2024Review
- The akinetic crisis in Parkinson´s disease- the upper end of a spectrum of subacute akinetic states.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- Analysis of post-market adverse events of istradefylline: a real-world study base on FAERS database.Scientific reports · 2024Article
- Chlorfenapyr poisoning: mechanisms, clinical presentations, and treatment strategies.World journal of emergency medicine · 2024Review
- Case report: Reversible encephalopathy caused by dyskinesia-hyperpyrexia syndrome.Frontiers in neurology · 2023Article
- Dyskinesia-hyperpyrexia syndrome in Parkinson's disease triggered by overdose of levodopa - a case report and literature review.Frontiers in neurology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinsonism-hyperpyrexia syndrome (PHS) and dyskinesia-hyperpyrexia syndrome (DHS) are rare but exhibit life-threatening complications in Parkinson's disease (PD). We herein presented two cases of PD patients and performed a comprehensive and comparative literature review for these two syndromes. The first case was diagnosed as PHS with cerebral salt wasting syndrome caused by abrupt withdrawal of antiparkinsonian medication. Her symptoms were gradually remitted with reinstitution of the medication. The second one was an early-stage PD patient diagnosed as DHS in association with abuse of antiparkinsonian drugs. Her symptoms were gradually remitted with reduced dosage of dopaminergic drugs. Results of literature reviews revealed a total of 56 and 13 cases of PHS and DHS, respectively, and they were more likely to occur in elderly and long-term PD patients. These two syndromes showed different female-to-male ratio, similar mortality, and different recovery time. There were stark differences between PHS and DHS, including triggers (abrupt drug stoppage versus drug abuse), symptoms (worsened tremor and rigidity versus continuous dyskinesia), and treatment (drug reinstitution versus drug reduction). In summary, our reports and the review provide new insights into PHS and DHS in association with PD and may facilitate rapid discrimination of the syndromes for timely and proper treatment to reduce mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.